Pacira Biosciences Inc Revenue per Employee (PCRX), current and historic results, rankings and more, quarterly fundamentals - CSIMarket
CSIMarket
 


Pacira Biosciences inc   (NASDAQ: PCRX)
 

Pacira Biosciences Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


Pacira Biosciences Inc 's Revenue per employee fell on a trailing twelve month basis to $ 896,624, but the productivity of Pacira Biosciences Inc 's employees remained above the company average.
Within the Healthcare sector Employees of 90 other companies have achieved higher revenue per employee. While Pacira Biosciences Inc 's total ranking has deteriorated compared to the previous quarter from 652 to 963. Pacira Biosciences Inc has 829 employees.


What is Sales per Employee Ratio?







PCRX Revenue per Employee (Sep 30 2026)
III. Quarter
(Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
Y / Y Revenue Change -1.59 % 6.24 % 5 % 5.14 % 6.49 %
Sales per Employee (TTM) $ 896,624 900,077 886,446 876,250 864,645
PCRX's Total Ranking # 963 # 652 # 1042 # 1122 #
Seq. Revenue Change -8.18 % 8.47 % -9.9 % 9.67 % -0.87 %


Revenue per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 64
Healthcare Sector # 91
Overall Market # 963

Revenue per Employee Statistics
High Average Low
$ 886,446 $ 511,197 $ 75,316
(Mar 31 2026)   (Sep 30 2013)



Financial Statements
Pacira Biosciences Inc 's Revenue MRQ $ 177 Millions Visit PCRX's Income Statement
Pacira Biosciences Inc 's Revenues TTM $ 743 Millions Visit PCRX's aggregate revenue growth
What are PCRX's Sales? Visit PCRX's Sales by Segment


  News about Pacira Biosciences inc Revenue per employee

Pacira BioSciences Grants Inducement Awards Amidst Promising Revenue Growth



TAMPA, Fla. Sept. 09, 2024 - Pacira BioSciences, Inc. a leading player dedicated to non-opioid pain management and regenerative health solutions, recently announced the provision of inducement awards to 17 new employees on September 4, 2024. These awards were granted under Pacira s Amended and Restated 2014 Inducement Plan with the intention of enticing these employees to join the company. The Compensation Committee of the Board of Directors duly approved these awards in compliance with Nasdaq Listing Rule 5635(c)(4).
Simultaneously, Pacira BioSciences Inc s stock has witnessed a commendable gain of 7.96% over the past five trading days. Moreover, the company s revenue per employee has displayed promising growth over the trailing twelve months, accumulating to an impressive $545,883. Specifically, the second quarter of 2024 experienced a 11.03% YoY revenue increase, reaching a cumulative value of $679 million, marking an all-time high for the company.




Other Ratios
Pacira Biosciences Inc 's Income per Employee
Employees in Major Pharmaceutical Preparations
Major Pharmaceutical Preparations Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
PCRX's Revenue per Employee versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for PCRX's Competitors
Revenue per Employee for PCRX's Suppliers
Revenue per Employee for PCRX's Customers

You may also want to know
PCRX's Sales Growth Rates PCRX's Pe Price to earnings ratio PCRX's Receivables Turnover Ratio PCRX's Stock Quote
PCRX's Net Income Growth Rates PCRX's Ps Price to Sales ratio PCRX's Sales per Employee PCRX's Asset Turnover Ratio
PCRX's Net Margin PCRX's Pb Price to Book ratio PCRX's Financial Strength Ratios PCRX's Dividend Payout Ratio
Date modified: 2026-11-07T13:19:36+00:00




Companies with similar Revenue per Employee for 12 months ending Sep 30 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Sep 30 2026Number of Employees Sep 30 2026
Madrigal Pharmaceuticals Inc   1,560,590.16 $ 1,427.940  Million 915 
Bristol myers Squibb Company  1,539,476.92 $ 50,033.000  Million 32,500 
Acadia Pharmaceuticals Inc   1,506,642.86 $ 1,202.301  Million 798 
Indivior Pharmaceuticals Inc   1,376,000.00 $ 1,376.000  Million 1,000 
Biogen Inc   1,372,973.33 $ 10,297.300  Million 7,500 
Supernus Pharmaceuticals inc   1,326,849.69 $ 865.106  Million 652 
Corcept Therapeutics Inc  1,320,064.38 $ 963.647  Million 730 
Travere Therapeutics Inc   1,309,927.57 $ 651.034  Million 497 
Lantheus Holdings Inc   1,309,212.07 $ 1,561.890  Million 1,193 
Ptc Therapeutics inc   1,166,048.44 $ 1,155.554  Million 991 
Abbvie Inc   1,158,140.35 $ 66,014.000  Million 57,000 
Biomarin Pharmaceutical Inc  1,134,780.19 $ 3,655.127  Million 3,221 
Bridgebio Pharma Inc   1,126,984.51 $ 945.540  Million 839 
Arvinas Inc   1,119,105.69 $ 275.300  Million 246 
Regeneron Pharmaceuticals Inc   1,096,443.87 $ 16,896.200  Million 15,410 
Ani Pharmaceuticals Inc  1,073,549.48 $ 1,041.343  Million 970 
Verastem Inc   983,294.12 $ 100.296  Million 102 
Syndax Pharmaceuticals Inc   971,244.97 $ 289.431  Million 298 
Ardelyx inc   957,505.11 $ 468.220  Million 489 
Axsome Therapeutics Inc   935,424.86 $ 865.268  Million 925 
Alphatec Holdings Inc   919,662.65 $ 839.652  Million 913 
Insmed Inc  888,846.15 $ 1,479.040  Million 1,664 
Carlisle Companies Incorporated  883,644.07 $ 5,213.500  Million 5,900 
Alkermes Plc   855,414.15 $ 1,753.599  Million 2,050 
Pfizer Inc  848,333.33 $ 63,625.000  Million 75,000 
Transmedics Group Inc   810,300.67 $ 727.650  Million 898 
Cerus Corporation  787,493.06 $ 226.798  Million 288 
Ars Pharmaceuticals Inc   749,300.61 $ 122.136  Million 163 
Phathom Pharmaceuticals Inc   740,919.14 $ 274.881  Million 371 
Emergent Biosolutions Inc   721,222.22 $ 649.100  Million 900 




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.